文献速递肝病消化道肿瘤与早癌

肝癌细胞系分析识别对肝细胞癌可能有效的药物及应答标志物

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
PubMed 文献 · Gastroenterology · 2019-05-04

研究对34株肝癌细胞系进行全外显子RNA和microRNA测序及126种蛋白定量,并筛选31种抗癌药物对细胞活力的影响。细胞系的蛋白、RNA和突变特征与增殖类肝细胞癌相似,研究识别了与药物应答相关的遗传改变和基因表达模式,这些信息可能用于筛选临床试验患者。

要点

  • 34株肝癌细胞系的蛋白、RNA和突变特征与增殖类肝细胞癌相似。
  • Ras-MAPK通路基因改变且依赖FGF19-FGFR4生存的细胞系对曲美替尼比FGFR4抑制剂更敏感。
  • TSC1/TSC2失活突变细胞系对雷帕霉素敏感,TP53失活突变细胞系对alisertib敏感。

核心结论

  • 肝癌细胞系可用于筛选可能对肝细胞癌治疗有效的药物和制剂。
  • 研究识别了与这些药物应答相关的遗传改变和基因表达模式。
  • 这些信息可能用于为临床试验选择患者。

研究设计与样本

  • 研究对34株肝癌细胞系进行全外显子RNA和microRNA测序及126种蛋白定量。
  • 筛选31种抗癌药物对细胞活力的影响。
  • 将细胞系的遗传、RNA和蛋白谱与原发肝细胞癌样本比较,寻找应答标志物。

主要发现

  • 细胞系的蛋白、RNA和突变特征与增殖类肝细胞癌相似,后者是最具侵袭性的肿瘤类型。
  • Ras-MAPK信号通路基因改变且依赖成纤维细胞生长因子19(FGF19)经FGF受体4(FGFR4)信号生存的细胞系对曲美替尼比FGFR4抑制剂更敏感。
  • FGF19扩增仅在保留肝细胞分化基因表达模式的肿瘤细胞中导致FGF19活性增加。
  • 研究识别了能降低具有肝细胞癌祖细胞亚类特征细胞活力的单药和联合方案。
  • TSC1和TSC2失活突变的细胞系对哺乳动物雷帕霉素靶蛋白抑制剂雷帕霉素敏感,TP53失活突变的细胞对Aurora激酶A抑制剂alisertib敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinomas (HCCs) are heterogeneous aggressive tumors with low rates of response to treatment at advanced stages. We screened a large panel of liver cancer cell lines (LCCLs) to identify agents that might be effective against HCC and markers of therapeutic response. METHODS: We performed whole-exome RNA and microRNA sequencing and quantification of 126 proteins in 34 LCCLs. We screened 31 anticancer agents for their ability to decrease cell viability. We compared genetic, RNA, and protein profiles of LCCLs with those of primary HCC samples and searched for markers of response. RESULTS: The protein, RNA and mutational signatures of the LCCLs were similar to those of the proliferation class of HCC, which is the most aggressive tumor type. Cell lines with alterations in genes encoding members of the Ras-MAPK signaling pathway and that required fibroblast growth factor (FGF)19 signaling via FGF receptor 4 for survival were more sensitive to trametinib than to FGF receptor 4 inhibitors. Amplification of FGF19 resulted in increased activity of FGF19 only in tumor cells that kept a gene expression pattern of hepatocyte differentiation. We identified single agents and combinations of agents that reduced viability of cells with features of the progenitor subclass of HCC. LCCLs with inactivating mutations in TSC1 and TSC2 were sensitive to the mammalian target of rapamycin inhibitor rapamycin, and cells with inactivating mutations in TP53 were sensitive to the Aurora kinase A inhibitor alisertib. Amplification of MET was associated with hypersensitivity to cabozantinib and the combination of sorafenib and inhibitors of MAP kinase 1 and MAP kinase2 had a synergistic antiproliferative effect. CONCLUSION: LCCLs can be screened for drugs and agents that might be effective for treatment of HCC. We identified genetic alterations and gene expression patterns associated with response to these agents. This information might be used to select patients for clinical trials.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Caruso S, Calatayud AL, Pilet J, et al. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology. 2019. PMID: 31063779. doi:10.1053/j.gastro.2019.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。